Header graphic for print
LimeGreenIP News

Tag Archives: Eli Lilly

Video-log – Patent law in Europe: What pharmaceutical companies need to know

With pharmaceutical competition in Europe continuing to evolve, established companies and new market entrants alike need to understand how key patent litigation tools are shaping the competitive landscape. Increasing competition within Europe’s pharmaceutical space makes knowing the market and understanding available patent protections more critical than ever for both well established and new market players.

Hogan Lovells wins ‘TMT Team of the Year’ at the Legal Business Awards 2018

We are delighted to have been awarded TMT Team of the Year at the Legal Business Awards 2018. The award recognises the team’s victory in the landmark Actavis v Eli Lilly Supreme Court case, which found that Actavis’ products infringed Lilly’s patents in the UK, France, Italy and Spain. The award follows feedback gathered from an expert

Hogan Lovells named MIP Global Firm of the Year

London, 9 March 2018 – Hogan Lovells global IP practice has been awarded the accolade of ‘Global IP Firm of the Year’ at the Managing Intellectual Property EMEA awards, in recognition of its market leading and innovative work on matters across Europe and beyond. The firm was shortlisted in 16 categories, also winning awards for:

IPMT Partner Featured in The Lawyer’s Hot 100 2018

Daniel Brook, partner in our London office has been included in the recently-published The Lawyer’s Hot 100 list. The prestigious list from leading UK legal magazine The Lawyer celebrates the most daring, innovative and creative lawyers in the UK from private practice, in-house and the Bar. Daniel is a patent litigator in the UK and was

UK Supreme Court hands down landmark ruling in favour of Eli Lilly

Following last Friday’s (7 July 2017) unusual move of advance publication of the outcome of the case, the UK Supreme Court now published the reasons for its decision in the long-running Actavis v Eli Lilly case. The reasons show that the UKSC found for Lilly under every point being considered. The result is that Actavis’ products

Hogan Lovells Successfully Acts for Eli Lilly in UK Supreme Court Patent Ruling

In an unusual move, the UK Supreme Court (UKSC) has given its key conclusions in the long running Actavis v Eli Lilly case ahead of giving the full judgment. The UKSC allowed Eli Lilly’s appeal and held that Actavis’ products directly infringe Lilly’s patent in the United Kingdom, France, Italy and Spain. The full judgment